SEC Comment Letter for Viela Bio, Inc. (CIK 0001734517) — Apr 17, 2020

Viela Bio, Inc. (CIK 0001734517)
Date: April 17, 2020 · CIK: 0001734517 · Accession: 0000000000-20-003362

View on Edgar

AI Filing Summary & Sentiment

Date

April 17, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Viela Bio, Inc. (CIK 0001734517)

Letter

April 17, 2020 Zhengbin (Bing) Yao, Ph.D. Chairman, President and Chief Executive Officer Viela Bio, Inc. One MedImmune Way First Floor, Area Two Gaithersburg, MD 20878 Re:Viela Bio, Inc. Draft Registration Statement on Form S-1 Submitted April 15, 2020 CIK No. 0001734517 Dear Dr. Yao: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John T. Rudy

Show Raw Text

April 17, 2020
Zhengbin (Bing) Yao, Ph.D.
Chairman, President and Chief Executive Officer
Viela Bio, Inc.
One MedImmune Way
First Floor, Area Two
Gaithersburg, MD 20878
Re:Viela Bio, Inc.
Draft Registration Statement on Form S-1
Submitted April 15, 2020
CIK No. 0001734517
Dear Dr. Yao:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       John T. Rudy

SecProbe.io